Want to see UNCY full AI Analyst Report?
UNCY Stock Chart & Stats
$5.40
$0.03(0.56%)
At close: 4:00 PM EDT
$5.40
$0.03(0.56%)
Day’s Range― - ―
52-Week Range$3.71 - $8.74
Previous CloseN/A
Volume52.73K
Average Volume (3M)2.27M
Market Cap
$153.48M
Enterprise Value$65.55
Total Cash (Recent Filing)$61.42M
Total Debt (Recent Filing)$671.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 18, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding27,855,257
10 Day Avg. Volume845,778
30 Day Avg. Volume2,269,657
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.71Price Target Upside542.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$2.85M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low reported debt reduces refinancing and interest-rate risk for a clinical-stage biopharma. This durable capital structure gives management flexibility to fund trials or pursue partnerships without immediate debt servicing pressure, preserving optionality over the next 2–6 months.
Improved Equity And Asset BaseEquity recovery from prior negative levels and higher total assets strengthen the balance sheet, improving creditor confidence and the company’s ability to negotiate financings or collaborations. This bolstered position materially lowers near-term solvency risk versus prior years.
Preliminary Cash RunwayA reported cash balance near $61M provides a meaningful near-term runway to support clinical programs and corporate costs. Although preliminary and unaudited, this liquidity materially reduces immediate funding urgency and supports execution of development milestones over the coming months.
Bears Say
No Product Revenue; Widening LossesThe company remains entirely development-stage with no commercial revenue and materially larger recent losses. Persistent operating deficits increase dependence on raising capital and raise the risk that future funding needs could constrain programs or dilute existing shareholders if operating losses continue.
Deep Negative Free Cash FlowSustained, large negative free cash flow indicates real cash burn rather than accounting distortions. Because cash outflows closely track reported losses, the company will need recurring external financing to sustain operations absent revenue, creating ongoing dilution and execution risk over the medium term.
Reliance On Equity Financing (dilution Risk)Expanding the at-the-market equity program gives financing optionality but signals reliance on public equity to fund operations. Frequent or sizable ATM sales can dilute shareholders and expose the company to market-access risk if conditions deteriorate, a structural funding vulnerability for a pre-revenue biotech.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics, Inc.’s price range in the past 12 months?
Unicycive Therapeutics, Inc. lowest stock price was $3.71 and its highest was $8.74 in the past 12 months.
What is Unicycive Therapeutics, Inc.’s market cap?
Unicycive Therapeutics, Inc.’s market cap is $153.48M.
When is Unicycive Therapeutics, Inc.’s upcoming earnings report date?
Unicycive Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 94 days.
How were Unicycive Therapeutics, Inc.’s earnings last quarter?
Unicycive Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.411.
Is Unicycive Therapeutics, Inc. overvalued?
According to Wall Street analysts Unicycive Therapeutics, Inc.’s price is currently Undervalued.
Does Unicycive Therapeutics, Inc. pay dividends?
Unicycive Therapeutics, Inc. does not currently pay dividends.
What is Unicycive Therapeutics, Inc.’s EPS estimate?
Unicycive Therapeutics, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Unicycive Therapeutics, Inc. have?
Unicycive Therapeutics, Inc. has 27,855,257 shares outstanding.
What happened to Unicycive Therapeutics, Inc.’s price movement after its last earnings report?
Unicycive Therapeutics, Inc. reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went up 7.8%.
Which hedge fund is a major shareholder of Unicycive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.71 (542.86% Upside)
$34.71 (542.86% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.14%
Trailing 12-Months
Company Description
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$34.71
▲(542.86% Upside)
Technical Analysis
Ownership Overview
16.28%
Insiders
3.56% Mutual Funds
20.41% Other Institutional Investors
51.06% Public Companies and
Individual Investors